More deaths, no benefit from malaria drug in VA virus study
A malaria drug widely touted by President Donald Trump for treating the new coronavirus showed no benefit in a large new study.
Researchers reported there were more than twice as many deaths among patients getting hydroxychloroquine than usual care. The analysis involved 368 men with COVID-19 in U.S. veterans hospitals.
Although it was not a rigorous experiment, it is the biggest report of results so far for the drug, with or without the antibiotic azithromycin, against the coronavirus.
The analysis was posted on an online site for researchers, but has not been reviewed by other scientists.